Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Pharmaceuticals Holding Co. is conducting a Phase I clinical study titled ‘An Open, Multicenter, Dose-escalation, and Dose-expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of SPH7485 Tablets in Patients With Advanced Solid Tumors.’ The study aims to assess the safety and effectiveness of SPH7485 tablets for treating advanced solid tumors, a significant step in cancer treatment research.
The intervention being tested is SPH7485, an experimental drug administered orally in doses ranging from 50 to 400 mg daily over a 21-day cycle. The primary goal is to evaluate its safety and initial efficacy in patients.
This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. The design is straightforward, aiming to gather data on the drug’s impact on patients with advanced solid tumors.
The study began on June 27, 2024, with primary completion expected soon. The latest update was submitted on August 15, 2025. These dates are crucial as they mark the progress and ongoing nature of the study.
The outcome of this study could significantly influence Shanghai Pharmaceuticals’ stock performance and investor sentiment, as successful results might enhance the company’s position in the competitive oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.